Skip to main content

ABCIXIMAB

ABCIXIMAB


BRAND NAME:- REOPRO 2mg /ml inj .


ABCIXIMAB is nonantigenic ,antiplatelet and antithrombotic drugs . These are the drug which interfere with platelet function and are useful in the prophylaxis of thromboembolic disorders.


PHARMACOLOGICAL & MECHANISM OF ACTION:-

It is the Fab fragment of a chimeric monoclonal antibody against GPIIb/IIIa, protein,but is relatively nonspecific and binds to some other surface proteins as well. Given along with Aspirin+ heparin during PCI it has markedly reduced the incidence of restenosis, subsequent MI and death. In the ISAR-REACT2 trial addition of ABCIXIMAB to clopidogrel(600mg oral loading dose) for PCI in high risk ACS patients, reduced ischaemic events by 25%. After a bolus dose, platelet aggregation remain inhibited for 12-24hr, while the remaining antibody is cleared from blood with a t½ of 10-30min.


PRECAUTIONS:-
ABCIXIMAB is nonantigenic. The main risk haemorrhage, incidence of which can be reduced by carefully managing the concomitant heparin therapy. Thrombocytopenia is another complication. It should not be used second time ,since risk of thrombocytopenia increases . Constipation, ileus and arrhythmias can occur. It is expensive, but is being used in unstable angina and as adjuvant to  coronary thrombolysis /PCI with stent placement.


DOSE:-0.25mg /kg  i.v . 10-60 min before PCI , followed by 10 ug / min  for 12hr.



USED:- use as a coronary artery disease, Acute coronary syndrome (ACSs),cerebrovascular disease, prosthetic heart valve and arteriovenous shunts, venous thromboembolism and peripheral vascular disease etc.


Labels:

Comments

Post a Comment

Popular posts from this blog

Cefpodoxime proxetil Uses, Side Effects, and More

 Cefpodoxime proxetil Brand name:- cefoprox ,cepodem,DOXCEF 100,200mg cap.  Cefpodoxime Proxetil is an antibiotic. It kills the bacteria by preventing them from forming the bacterial protective covering (cell wall) which is needed for them to survive. Pharmacodynamic:-  Cefpodoxime is shown to be effective against most Gram positive and Gram negative bacteria, except Pseudomonas aeruginosa, Enterococcus, and Bacteroides fragilis. Mechanism of action:-  Cefpodoxime is active against a wide spectrum of Gram-positive and Gram-negative bacteria. Cefpodoxime is stable in the presence of beta-lactamase enzymes. As a result, many organisms resistant to penicillins and cephalosporins, due to their production of beta-lactamase, may be susceptible to cefpodoxime. Cefpodoxime is inactivated by certain extended spectrum beta-lactamases. The bactericidal activity of cefpodoxime results from its inhibition of cell wall synthesis. The active metabolite of cefpodoxime binds preferentially to penicilli
Post a Comment
Read more

Cephalexin ( ZYD ) ( Cefalexin ) Uses, Side Effects, and More

 Cephalexin (ZYD) (Cefalexin) Brand name:-  Cephacillin 250,500mg cap; Sporidex, Alcephin,Cephaxin cap. Cephalexin (also called Cefalexin)  is the most common used orally effective first generation cephalosporin , similar in spectrum to cefazolin , but less active against penicillinase producing staphylococci and H. Influenza. Plasma protein binding is low; it attains High concentration in bile and is excreted unchanged in urine; t½ - 60min. Pharmacodynamic:-  Cephalexin (also called Cefalexin) is a first generation cephalosporin antibiotic. It is one of the most widely prescribed antibiotics, often used for the treatment of superficial infections that result as complications of minor wounds or lacerations.Label It is effective against most gram-positive bacteria through its inihibition of the cross linking reaction between N-acetyl muramicacid and N-acetylglucosamine in the cell wall, leading to cell lysis. Pharmacokinetics:- Cephalexin is rapidly and almost completely absorbed from t
Post a Comment
Read more

BASILIXIMAB Uses, Side Effects, and More

 BASILIXIMAB BRAND NAME:- Simulect   BASILIXIMAB is another anti CD - 25 antibody with higher affinity for the IL-2 receptor, but shorter plasma t½ (1 week) . is a monoclonal antibody used to prevent rejection in kidney transplants. It is a chimeric mouse-human monoclonal antibody to the α chain (CD25) of the IL-2 receptor of T cells. It is used in combination with other medicines used to prevent organ rejection. PHARMACODYNAMIC:- Basiliximab functions as an IL-2 receptor antagonist. Specifically it inhibits IL-2-mediated activation of lymphocytes, a critical pathway in the cellular immune response involved in allograft rejection.  MECHANISM OF ACTION:-  Basiliximab competes with IL-2 to bind to the alpha chain subunit of the IL2 receptor on the surface of the activated T lymphocytes and thus prevents the receptor from signaling. This prevents T cells from replicating and also from activating B cells, which are responsible for the production of antibodies, which would bind to the trans
1 comment
Read more